Clinical trials: Non-small Lung Cancer
Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC)
QLS5132 Combination Therapy in Advanced Solid Tumors
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and effectiveness of the investigational drug QLS5132 (injectable) in combination with other therapies for participants with advanced…
- Conditions
- Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC), Endometrial Cancer, Advanced Solid Tumors
- Trial name
- NCT07453394
- Testing
- QLS5132; Bevacizumab, QLS5132; Platinum; Bevacizumab, QLS5132; Olaparib; Bevacizumab
- Volunteers
- 626 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Lung Cancer, Non-Small Cell
Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer
The primary purpose of this study is to evaluate the safety and tolerability of the combination therapy of trametinib and docetaxel with growth factor support in Japanese subjects with Stage IV or a postoperative recurrence…
- Trial name
- NCT01938456
- Testing
- Trametinib, Docetaxel, Filgrastim
- Sponsor
- GlaxoSmithKline
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer
Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
This clinical trial studies image-guided hypofractionated radiation therapy (RT) when given together with hypofractionated RT boost and combination chemotherapy in treating patients with stage II-III non-small cell lung cancer…
- Conditions
- Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
- Trial name
- NCT01345851
- Testing
- hypofractionated radiation therapy, laboratory biomarker analysis, image-guided radiation therapy
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Non-Small Cell Lung Cancer
Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC
This is an open-label, single institution, phase II study of Sorafenib in combination with docetaxel and carboplatin in patients with advanced non-small cell lung cancer.
- Trial name
- NCT00647426
- Testing
- Sorafenib + Docetaxel/Carboplatin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Lung Cancer
High-Dose 3-Dimensional Conformal Radiation Therapy in Treating Patients With Inoperable Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer
RATIONALE: Using computer systems that create a 3-dimensional picture of the tumor to plan treatment may enable doctors to provide more effective radiation therapy that will cause less damage to normal tissue.
- Trial name
- NCT00062335
- Testing
- radiation therapy
- Where
- 7 sites in Belgium, France and 1 more
- Volunteers
- 14 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Early Lung Cancer
Serplulimab Combined With Cryoablation for Early-Stage Non-Small Cell Lung Cancer
The goal of this clinical trial is to learn if serplulimab combined with cryoablation can effectively treat early-stage non-small cell lung cancer (NSCLC) in adults who are not eligible for or decline surgery or radiotherapy.
- Trial name
- NCT07064876
- Testing
- Serplulimab, CT-guided Cryoablation
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Xi Junjie
Non-Small Cell Lung Cancer
Hybrid Prehabilitation Before Thoracic Surgery
Background and study aims: Lung cancer is a leading cause of cancer-related deaths worldwide. Patients with non-small cell lung cancer often undergo lung surgery to remove the tumor.
- Trial name
- HYBREATH (NCT06866717)
- Testing
- Hybrid prehabilitation, Center-based prehabilitation
- Where
- France
- Volunteers
- 38 people
- Sponsor
- ADIR Association
Lung Cancer, Non-small Cell Lung Cancer
Effects of Infusion Timing on Treatment Response in Solid Tumors
This study evaluates whether the time of day when immunotherapy is given affects clinical outcomes. It includes patients eligible for PD-1 (programmed cell death protein 1) or PD-L1 (programmed death-ligand 1) inhibitor treatment…
- Conditions
- Lung Cancer, Non-small Cell Lung Cancer, Metastatic Lung Cancer, Head and Neck Cancer
- Trial name
- TIMED (NCT07630168)
- Testing
- PD-1/PD-L1 inhibitor monotherapy - 4 cycles before 12:00PM, PD-1/PD-L1 inhibitor monotherapy - 4 cycles after 3 PM, PD-1 inhibitor monotherapy - 2 cycles before 12:00PM
- Where
- United States
- Volunteers
- 238 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non-Small Cell Lung Cancer
Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer
This study is being done to determine the overall progression-free survival (PFS) in patients with advanced or metastatic (Stage IIIB - pleural effusion/IV), non-squamous histology NSCLC treated with metronomic chemotherapy plus…
- Trial name
- NCT00655850
- Testing
- Paclitaxel, Gemcitabine, Avastin
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Alabama at Birmingham
Non-small Cell Lung Cancer
Stereotactic Precision And Conventional Radiotherapy Evaluation
A randomized phase II study for medically inoperable stage I non-small cell lung cancer where stereotactic body radiotherapy in three fractions to 66 Gy is compared with conventionally fractionated radiotherapy to 70 Gy in 35…
- Trial name
- SPACE (NCT01920789)
- Testing
- Stereotactic radiotherapy, Conventionally fractionated radiotherapy
- Volunteers
- 102 people
- Sponsor
- Ass. Prof. Jan Nyman
Non Small Cell Lung Cancer
Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy
The purpose of this randomized phase II trial is to determine the clinical feasibility - in terms of patients without dose limiting toxicities or premature treatment withdrawal or death - of the combination of Cisplatin and…
- Trial name
- NCT00349089
- Testing
- Pemetrexed, Cisplatin, Vinorelbine
- Where
- 14 sites in Belgium, Germany and 1 more
- Volunteers
- 132 people
- Sponsor
- Thoraxklinik-Heidelberg gGmbH
Advanced Solid Tumors
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5.
- Trial name
- NCT06730750
- Testing
- BMS-986490, Bevacizumab
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 360 people
- Sponsor
- Bristol-Myers Squibb
Mediastinal Lymphadenopathy, Hilar Lymphadenopathy
Endobronchial Ultrasound Needle Aspiration With and Without Suction
The main purpose of the present study is to compare the diagnostic yield of different aspiration techniques in Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA) in the diagnosis of hilar/mediastinal adenopathy
- Conditions
- Mediastinal Lymphadenopathy, Hilar Lymphadenopathy, Lymphoma, Lung Neoplasms
- Trial name
- NCT05110950
- Testing
- No suction EBUS-TBNA, Passive suction through dedicated EBUS-TBNA syringe, Manual applied suction EBUS-TBNA through a pistol-grip syringe holder
- Where
- Italy
- Volunteers
- 306 people
- Sponsor
- Università Politecnica delle Marche
Squamous Cell Lung Cancer
Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)
To evaluate the overall survival (OS) of patients with advanced squamous cell lung cancer receiving the combination of gemcitabine/carboplatin either with or without Iniparib.
- Trial name
- ECLIPSE (NCT01082549)
- Testing
- gemcitabine/carboplatin, gemcitabine/carboplatin plus Iniparib
- Where
- 142 sites in United States, Belgium and 12 more
- Volunteers
- 780 people
- Sponsor
- Sanofi
Non-small Cell Lung Cancer
Efficacy Study of Integrated TCM Combined With Chemotherapy in Postoperative NSCLC Patients
The investigators performed a multi-center, randomized, controlled, double-blind, prospective study on evaluating effect of chemotherapy combined with or without integrated TCM on quality of life (QOL) of postoperative Non-small…
- Trial name
- NCT01441752
- Testing
- TCM
- Where
- 2 sites in China
- Volunteers
- 349 people, healthy volunteers welcome
- Sponsor
- xuling
Small Cell Lung Cancer, Non-small Cell Lung Cancer
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
This amended expansion phase of the protocol is to further the experience at a dose level of 150 mg CPT eq/m2 in patients with Stage IV non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) and to test for…
- Trial name
- NCT00455052
- Testing
- XMT-1001
- Where
- 12 sites in United States
- Volunteers
- 30 people
- Sponsor
- Mersana Therapeutics
Non-small Cell Lung Cancer
A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation
To assess the efficacy and safety of Almonertinib versus platinum-based chemotherapy as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutation.
- Trial name
- NCT04951648
- Testing
- Almonertinib, chemotherapy
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases
This is an open-label, single centre, Phase I study to determine the brain exposure of [11C]osimertinib in patients with EGFRm NSCLC with brain metastases.
- Trial name
- ODIN-BM (NCT03463525)
- Testing
- Osimertinib, [11C]osimertinib
- Where
- Sweden
- Volunteers
- 4 people
- Sponsor
- AstraZeneca
Non-small-cell Lung Cancer With Somatic EGFR Mutations
Biomarker Study Accompanying the AIO-TRK-0114 Study (MARBLE)
To compare the efficacy of afatinib maintenance with pemetrexed maintenance following induction therapy with platinum/ pemetrexed in patients with metastatic EGFR mutated non-small-cell lung cancer progressing after first-line…
- Trial name
- Trans-MARBLE (NCT02595840)
- Testing
- Afatinib, Pemetrexed
- Volunteers
- 4 people
- Sponsor
- Universität Duisburg-Essen
Non-small Cell Lung Cancer
Analysis of Driver Gene Mutation in Early Stage Non-small Cell Lung Cancer
Analysis of driver gene variation in early stage non-small cell lung cancer
- Trial name
- NCT04266691
- Testing
- nonIntervention
- Volunteers
- 237 people
- Sponsor
- Zhejiang Cancer Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.